MX2022001772A - Formulaciones de isotretinoina y usos y metodos de las mismas. - Google Patents
Formulaciones de isotretinoina y usos y metodos de las mismas.Info
- Publication number
- MX2022001772A MX2022001772A MX2022001772A MX2022001772A MX2022001772A MX 2022001772 A MX2022001772 A MX 2022001772A MX 2022001772 A MX2022001772 A MX 2022001772A MX 2022001772 A MX2022001772 A MX 2022001772A MX 2022001772 A MX2022001772 A MX 2022001772A
- Authority
- MX
- Mexico
- Prior art keywords
- isotretinoin
- methods
- formulations
- isotretinoin formulations
- ichthyosis
- Prior art date
Links
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 title abstract 4
- 229960005280 isotretinoin Drugs 0.000 title abstract 4
- 238000009472 formulation Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002500 effect on skin Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 206010021198 ichthyosis Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Dispersion Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se proporcionan en la presente formulaciones de isotretinoína novedosas que proporcionan un sistema mejorado de administración dérmica, dirigida para el fármaco isotretinoína con actividad termodinámica mejorada que no utiliza ningún nivel a un pequeño nivel de etanol con respecto a productos de gel de isotretinoína existentes, y métodos para tratamiento de ictiosis y otras condiciones de la piel que utilizan las mismas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562248760P | 2015-10-30 | 2015-10-30 | |
US201662301759P | 2016-03-01 | 2016-03-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022001772A true MX2022001772A (es) | 2022-03-22 |
Family
ID=58631077
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018004984A MX2018004984A (es) | 2015-10-30 | 2016-10-26 | Formulaciones de isotretinoina y usos y metodos de las mismas. |
MX2022001772A MX2022001772A (es) | 2015-10-30 | 2018-04-23 | Formulaciones de isotretinoina y usos y metodos de las mismas. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018004984A MX2018004984A (es) | 2015-10-30 | 2016-10-26 | Formulaciones de isotretinoina y usos y metodos de las mismas. |
Country Status (11)
Country | Link |
---|---|
US (3) | US10933018B2 (es) |
EP (1) | EP3368009A1 (es) |
JP (2) | JP6901670B2 (es) |
KR (2) | KR20220082095A (es) |
CN (2) | CN113577050A (es) |
AU (2) | AU2016346203B2 (es) |
BR (1) | BR112018008556A2 (es) |
CA (1) | CA3002387C (es) |
MX (2) | MX2018004984A (es) |
RU (1) | RU2018119510A (es) |
WO (1) | WO2017074982A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3368009A1 (en) | 2015-10-30 | 2018-09-05 | Patagonia Pharmaceuticals, LLC | Isotretinoin formulations and uses and methods thereof |
CN116528820A (zh) * | 2021-05-14 | 2023-08-01 | 莱雅公司 | 包含护肤活性成分和两种聚甘油脂肪酸酯的组合物 |
Family Cites Families (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1988009788A1 (en) | 1987-06-12 | 1988-12-15 | Molecular Design International, Inc. | Topical prodrugs for treatment of acne and skin diseases |
ZA879063B (en) * | 1986-12-22 | 1989-04-26 | Hoffmann La Roche | Use of 13-cis retinoic acid |
AU618517B2 (en) | 1986-12-23 | 1992-01-02 | Eugene J. Van Scott | Additives enhancing topical actions of therapeutic agents |
US6051609A (en) | 1997-09-09 | 2000-04-18 | Tristrata Technology, Inc. | Additives enhancing the effect of therapeutic agents |
US5342957A (en) | 1988-11-29 | 1994-08-30 | Janssen Pharmaceutica N.V. | Benzimidazoles useful in treating epithelial disorders |
US5075340A (en) * | 1989-05-22 | 1991-12-24 | Iowa State University Research Foundation | Retinoic acid glucuronide preparations for application to the skin |
AU618198B2 (en) * | 1989-05-22 | 1991-12-12 | Iowa State University Research Foundation Inc. | Water-soluble vitamin a preparations for application to the skin |
CA2063576C (en) | 1989-06-07 | 1994-01-25 | Gail S. Bazzano | Slow release vehicles for minimizing skin irritancy of topical compositions |
CA2037150C (en) | 1990-03-27 | 1999-12-28 | Guenter Gross | Retinoids |
US5051449A (en) | 1991-02-27 | 1991-09-24 | Kligman Albert M | Treatment of cellulite with retinoids |
GB9125712D0 (en) * | 1991-12-03 | 1992-01-29 | Smithkline Beecham Plc | Skin care composition |
US6093706A (en) | 1992-03-04 | 2000-07-25 | Bioresponse, L.L.C. | Combined dehydroepiandrosterone and retinoid therapy for epithelial disorders |
US5252604A (en) * | 1992-07-10 | 1993-10-12 | Hoffmann-La Roche Inc. | Compositions of retinoic acids and tocopherol for prevention of dermatitis |
DK0730441T3 (da) | 1993-11-12 | 2002-03-18 | Procter & Gamble | Deskvamationspræparater, der indeholder salicylsyre og zwitterioniske forbindelser |
FR2730930B1 (fr) | 1995-02-27 | 1997-04-04 | Oreal | Utilisation d'inhibiteurs de no-synthase pour diminuer l'effet irritant cutane de produits utilises dans le domaine cosmetique ou pharmaceutique |
FR2738745B1 (fr) | 1995-09-15 | 1997-10-24 | Cird Galderma | Nouvelles compositions a base d'un melange synergetique entre au moins un ligand de vdr et un retinoide, et leurs utilisations |
US5834513A (en) | 1996-04-25 | 1998-11-10 | Avon Products, Inc. | Oxa diacids and related compounds for treating skin conditions |
US5847003A (en) | 1996-06-04 | 1998-12-08 | Avon Products, Inc. | Oxa acids and related compounds for treating skin conditions |
US6008254A (en) * | 1997-05-09 | 1999-12-28 | Kligman; Douglas E. | Method of treating skin disorders with high-strength tretinoin |
US6599513B2 (en) | 1997-05-27 | 2003-07-29 | Sembiosys Genetics Inc. | Products for topical applications comprising oil bodies |
US6159485A (en) | 1999-01-08 | 2000-12-12 | Yugenic Limited Partnership | N-acetyl aldosamines, n-acetylamino acids and related n-acetyl compounds and their topical use |
US6335023B1 (en) | 1999-06-30 | 2002-01-01 | Ruey J. Yu | Oligosaccharide aldonic acids and their topical use |
US6967023B1 (en) | 2000-01-10 | 2005-11-22 | Foamix, Ltd. | Pharmaceutical and cosmetic carrier or composition for topical application |
US6551605B2 (en) | 2001-04-06 | 2003-04-22 | Haarmann & Reimer | Diesters or polyesters of naphthalene dicarboxylic acid as solubilizer/stabilizer for retinoids |
WO2003057162A2 (en) | 2002-01-04 | 2003-07-17 | Combinatorx, Incorporated | Combination for the treatment of immunoinflammatory disorders and proliferative skin diseases |
US20070292461A1 (en) | 2003-08-04 | 2007-12-20 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
AU2004266502B2 (en) | 2002-10-25 | 2010-09-23 | Foamix Pharmaceuticals Ltd. | Penetrating pharmaceutical foam |
US7820145B2 (en) * | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US20070292355A1 (en) | 2002-10-25 | 2007-12-20 | Foamix Ltd. | Anti-infection augmentation foamable compositions and kit and uses thereof |
US20040214215A1 (en) | 2003-03-07 | 2004-10-28 | Yu Ruey J. | Bioavailability and improved delivery of alkaline pharmaceutical drugs |
WO2005009342A2 (en) | 2003-07-16 | 2005-02-03 | Pharmacia Corporation | Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith |
US8486374B2 (en) * | 2003-08-04 | 2013-07-16 | Foamix Ltd. | Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses |
US8795693B2 (en) | 2003-08-04 | 2014-08-05 | Foamix Ltd. | Compositions with modulating agents |
CA2555121A1 (en) | 2004-02-04 | 2005-08-25 | Foamix Ltd. | Cosmetic and pharmaceutical foam with solid matter |
NZ550026A (en) | 2004-03-22 | 2009-10-30 | Celgene Corp | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of skin diseases or disorders |
ES2747926T3 (es) | 2004-09-27 | 2020-03-12 | Special Water Patents B V | Métodos y composiciones para el tratamiento de agua |
US20060177392A1 (en) | 2005-02-10 | 2006-08-10 | William Walden | Oil-based composition for acne |
FR2889662B1 (fr) | 2005-08-11 | 2011-01-14 | Galderma Res & Dev | Emulsion de type huile-dans-eau pour application topique en dermatologie |
FR2892936A1 (fr) | 2005-11-10 | 2007-05-11 | Galderma Res & Dev | Composition pharmaceutique ou cosmetique, et procede de solubilisation mixte pour preparer la composition. |
WO2007103555A2 (en) | 2006-03-08 | 2007-09-13 | Nuviance, Inc. | Transdermal drug delivery compositions and topical compositions for application on the skin |
WO2008007224A2 (en) | 2006-03-31 | 2008-01-17 | Stiefel Research Australia Pty Ltd | Foamable suspension gel |
WO2008070116A2 (en) | 2006-12-04 | 2008-06-12 | Concert, Llc | Topical compositions for treatment of skin conditions |
US8846374B2 (en) | 2006-12-12 | 2014-09-30 | E I Du Pont De Nemours And Company | Carotenoid production in a recombinant oleaginous yeast |
AU2008210557B2 (en) | 2007-01-30 | 2013-08-01 | Cypress Pharmaceutical, Inc. | Hyaluronate compositions |
WO2009072007A2 (en) | 2007-12-07 | 2009-06-11 | Foamix Ltd. | Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof |
US8697098B2 (en) | 2011-02-25 | 2014-04-15 | South Dakota State University | Polymer conjugated protein micelles |
US20120164087A1 (en) | 2009-04-24 | 2012-06-28 | Carter Daniel C | Human Serum Albumin-Based Topical Ointment for Treatment of Acne, Psoriasis, Egfr-Induced Toxicity, Premature Skin Aging and Other Skin Conditions |
CA2760186C (en) | 2009-04-28 | 2019-10-29 | Foamix Ltd. | Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
EP2432553A2 (en) * | 2009-05-20 | 2012-03-28 | Ranbaxy Laboratories Limited | Liquid dosage forms of isotretinoin |
CA2762394C (en) | 2009-05-20 | 2016-07-19 | Ranbaxy Laboratories Limited | Topical retinoid solutions |
CA2769625C (en) | 2009-07-29 | 2017-04-11 | Foamix Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
CA2769677A1 (en) | 2009-07-29 | 2011-02-03 | Foamix Ltd. | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
EP2482800A4 (en) | 2009-09-30 | 2013-10-30 | Stiefel Res Australia Pty Ltd | COSMETIC FOAM |
US20120064135A1 (en) * | 2010-09-15 | 2012-03-15 | Norac Pharma | Benzoyl Peroxide Composition, Methods for Making Same, and Pharmaceutical or Cosmetic Formulations Comprising Same, and Uses Thereof |
WO2012053013A2 (en) * | 2010-10-21 | 2012-04-26 | Cadila Healthcare Limited | Pharmaceutical compositions of anti-acne agents |
CN102805724A (zh) * | 2011-08-31 | 2012-12-05 | 山东方明药业集团股份有限公司 | 维a酸乳膏及其制备方法 |
EP2802608A4 (en) | 2012-01-12 | 2015-08-05 | Univ Yale | COMPOUNDS AND METHODS FOR ENHANCED DEGRADATION OF TARGET PROTEINS AND OTHER POLYPEPTIDES BY E3 UBIQUITIN LIGASE |
WO2013138744A1 (en) | 2012-03-16 | 2013-09-19 | M. Alphabet 1, Llc | Compositions for the treatment of skin disorders |
US9018236B2 (en) | 2012-03-22 | 2015-04-28 | Precision Dermatology, Inc. | Cyclodextrin-based microemulsions, and dermatological uses thereof |
US20150119435A1 (en) | 2012-05-11 | 2015-04-30 | Yale University | Compounds useful for promoting protein degradation and methods using same |
FR2991175B1 (fr) * | 2012-06-01 | 2014-12-19 | Galderma Res & Dev | Compositions pharmaceutiques topiques de type emulsion h/e contenant un retinoide |
FR2991178B1 (fr) | 2012-06-01 | 2014-06-27 | Galderma Res & Dev | Compositions topiques de type gel aqueux sous forme de suspension homogene d'un principe actif de la classe des retinoides contenant au moins une silice hydrophobe. |
FR2991172A1 (fr) | 2012-06-01 | 2013-12-06 | Galderma Res & Dev | Compositions pharmaceutiques topiques comprenant des microcapsules |
FR2991174B1 (fr) | 2012-06-01 | 2014-12-26 | Galderma Res & Dev | Composition dermatologique comprenant des oleosomes et des retinoides, son procede de preparation et son utilisation |
WO2013178749A1 (fr) | 2012-06-01 | 2013-12-05 | Galderma Research & Development | Nanocapsules lipidiques comprenant un rétinoide, nanodispersion et composition les contenant, leur procédé de préparation et leur utilisation en dermatologie |
FR3000396A1 (fr) | 2012-12-31 | 2014-07-04 | Galderma Res & Dev | Combinaison de laropiprant et de doxycycline pour le traitement de la rosacee |
FR3000397A1 (fr) | 2012-12-31 | 2014-07-04 | Galderma Res & Dev | Combinaison de laropiprant et d'ivermectine pour le traitement de la rosacee |
FR3000394A1 (fr) | 2012-12-31 | 2014-07-04 | Galderma Res & Dev | Combinaison de laropiprant et de metronidazole pour le traitement de la rosacee |
FR3000395A1 (fr) | 2012-12-31 | 2014-07-04 | Galderma Res & Dev | Combinaison de laropiprant et d'oxymetazoline pour le traitement de la rosacee |
FR3000398A1 (fr) | 2012-12-31 | 2014-07-04 | Galderma Res & Dev | Combinaison de laropiprant et de brimonidine pour le traitement de la rosacee |
FR3000399B1 (fr) | 2012-12-31 | 2015-03-27 | Galderma Res & Dev | Utilisation topique du laropiprant pour le traitement de la rosacee |
US20140249490A1 (en) | 2013-03-04 | 2014-09-04 | J&E Solutions, Llc | Methods for Prevention and/or Treatment of Capsular Contracture |
US20160128944A1 (en) | 2013-06-04 | 2016-05-12 | Vyome Biosciences Pvt. Ltd. | Coated particles and compositions comprising same |
US20150164907A1 (en) | 2013-11-17 | 2015-06-18 | Angion Biomedica Corp. | Compositions and methods for treating disease |
AU2014359195B2 (en) | 2013-12-04 | 2020-02-27 | Galderma Research & Development | Lipid microcapsules preferably comprising a lipophilic active substance and composition containing same, method for the production thereof, and use of same in dermatology and in cosmetics |
WO2015092602A1 (en) | 2013-12-17 | 2015-06-25 | Ranbaxy Laboratories Limited | Topical pharmaceutical composition of a retinoid |
MA40313A (fr) * | 2014-06-02 | 2017-04-05 | Sun Pharmaceutical Ind Ltd | Composition pharmaceutique à base d'isotrétinoïne destinée à la voie orale |
WO2016026527A1 (en) | 2014-08-20 | 2016-02-25 | Amantin Experts | Compositions and methods for controlled moisturizing and release of active ingredients |
EP3368009A1 (en) | 2015-10-30 | 2018-09-05 | Patagonia Pharmaceuticals, LLC | Isotretinoin formulations and uses and methods thereof |
-
2016
- 2016-10-26 EP EP16860643.2A patent/EP3368009A1/en active Pending
- 2016-10-26 KR KR1020227018704A patent/KR20220082095A/ko not_active Application Discontinuation
- 2016-10-26 CN CN202110920456.XA patent/CN113577050A/zh active Pending
- 2016-10-26 AU AU2016346203A patent/AU2016346203B2/en active Active
- 2016-10-26 WO PCT/US2016/058746 patent/WO2017074982A1/en active Application Filing
- 2016-10-26 CN CN201680063866.4A patent/CN108348456B/zh active Active
- 2016-10-26 CA CA3002387A patent/CA3002387C/en active Active
- 2016-10-26 KR KR1020187014948A patent/KR102406880B1/ko active IP Right Grant
- 2016-10-26 RU RU2018119510A patent/RU2018119510A/ru not_active Application Discontinuation
- 2016-10-26 JP JP2018542677A patent/JP6901670B2/ja active Active
- 2016-10-26 MX MX2018004984A patent/MX2018004984A/es unknown
- 2016-10-26 US US15/772,456 patent/US10933018B2/en active Active
- 2016-10-26 BR BR112018008556A patent/BR112018008556A2/pt not_active Application Discontinuation
-
2018
- 2018-04-23 MX MX2022001772A patent/MX2022001772A/es unknown
-
2020
- 2020-05-15 US US16/875,710 patent/US11471408B2/en active Active
-
2021
- 2021-05-19 JP JP2021084613A patent/JP7175038B2/ja active Active
- 2021-07-22 AU AU2021206858A patent/AU2021206858B2/en active Active
-
2022
- 2022-07-13 US US17/864,208 patent/US20220362148A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2018537524A (ja) | 2018-12-20 |
KR102406880B1 (ko) | 2022-06-08 |
KR20220082095A (ko) | 2022-06-16 |
CN108348456A (zh) | 2018-07-31 |
JP7175038B2 (ja) | 2022-11-18 |
AU2021206858A1 (en) | 2021-08-12 |
US11471408B2 (en) | 2022-10-18 |
CA3002387A1 (en) | 2017-05-04 |
US10933018B2 (en) | 2021-03-02 |
EP3368009A4 (en) | 2018-09-05 |
CN113577050A (zh) | 2021-11-02 |
MX2018004984A (es) | 2018-09-12 |
KR20180075616A (ko) | 2018-07-04 |
CN108348456B (zh) | 2021-09-17 |
AU2021206858B2 (en) | 2023-05-04 |
AU2016346203A1 (en) | 2018-05-24 |
JP6901670B2 (ja) | 2021-07-14 |
US20220362148A1 (en) | 2022-11-17 |
RU2018119510A (ru) | 2019-12-05 |
JP2021121617A (ja) | 2021-08-26 |
CA3002387C (en) | 2024-04-02 |
EP3368009A1 (en) | 2018-09-05 |
AU2016346203B2 (en) | 2021-05-27 |
BR112018008556A2 (pt) | 2018-10-23 |
US20180318245A1 (en) | 2018-11-08 |
WO2017074982A1 (en) | 2017-05-04 |
US20200297627A1 (en) | 2020-09-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12018500586A1 (en) | Farnesoid x receptor agonists and uses thereof | |
MX2020009780A (es) | Compuestos de inhibidor de autotaxina. | |
MX2023000320A (es) | Metodos para modular los niveles de farmaco en plasma mediante el uso de eritrohidroxibupropion. | |
BR112017024384A2 (pt) | bactérias modificadas para reduzir hiperfenilalaninemia | |
MX2015009106A (es) | Composiciones de solución sólida y su uso en el tratamiento del dolor intenso. | |
MX2019010735A (es) | Sistemas y metodos para la produccion dirigida de una proteina terapeutica dentro de una celula objetivo. | |
MX2016008448A (es) | Conjugados de var2csa-farmaco. | |
MX2015010791A (es) | Metodos para tratar el cancer y prevenir la resistencia a farmacos. | |
PH12017501095A1 (en) | Piperidine derivatives as hdac1/2 inhibitors | |
MX2015009058A (es) | Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias. | |
PH12016500863A1 (en) | Tetracyclic autotaxin inhibitors | |
MX2015009045A (es) | Composiciones y metodos para tratar el dolor severo. | |
AU2016206832A8 (en) | Non-invasive systems and methods for treatment of a host carrying a virus with photoactivatable drugs | |
EP3554435A4 (en) | SYSTEMS AND METHODS FOR DELIVERY OF MEDICINAL PRODUCTS TO RETINAL TISSUE | |
MX2022001772A (es) | Formulaciones de isotretinoina y usos y metodos de las mismas. | |
MX2016006544A (es) | Witanolidos utiles para el tratamiento de enfermedades neurodegenerativas. | |
PH12017501979A1 (en) | Pharmaceutical compound | |
PH12020500472A1 (en) | Autotaxin inhibitor compounds | |
SG10201809418VA (en) | New administration routes of insulin, insulin analogs or derivatives of insulin | |
PH12017501982A1 (en) | Pharmaceutical compound | |
GB2524930A (en) | Desensitizing drug products containing lidocaine, thymol and ethanol | |
MX2016010919A (es) | 4-bencilsulfonil-2-butenonitrilo. | |
RU2012146162A (ru) | Способ профилактики стресса при иммобилизации в эксперименте | |
UA104582U (uk) | Спосіб лікування неускладненої варикозної хвороби | |
IN2014MU00367A (es) |